Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine maintenance after autologous hematopoietic stem cell transplantation in acute myeloid leukemia
ChiCTR1900024515Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: Complete remission of hematology on morphology, Minimal residual disease and 4 more. Started Aug 2019; status: recruiting.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR1900024515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024515.